Referral for "Neoadjuvant Chemotherapy" for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes.
Athanasios DellisRoubini ZakopoulouAndromachi KougioumtzopoulouKimon TzannisKonstantinos KoutsoukosCharalampos FragkoulisEfthymios KostourosAthanasios PapatsorisIoannis VarkarakisKonstantinos StravodimosEleni BoutatiStamata PagoniMiltiadis SeferlisMichael ChrisofosVasilios KoulouliasKonstantinos NtoumasCharalambos DeliveliotisConstantine ConstantinidesMeletios A DimopoulosAristotelis BamiasPublished in: Cancer management and research (2021)
Real-world muscle invasive bladder cancer patients who receive neoadjuvant chemotherapy are characterized by more advanced diseases and less frequent radical surgery than those included in clinical trials. Nevertheless, outcomes were comparable and, therefore, offering patients with stage II-IVA muscle invasive bladder cancer neoadjuvant chemotherapy after assessment by multidisciplinary tumor boards should be strongly encouraged.
Keyphrases
- neoadjuvant chemotherapy
- muscle invasive bladder cancer
- locally advanced
- lymph node
- sentinel lymph node
- clinical trial
- minimally invasive
- rectal cancer
- squamous cell carcinoma
- radiation therapy
- coronary artery bypass
- quality improvement
- type diabetes
- metabolic syndrome
- coronary artery disease
- percutaneous coronary intervention